Search

Galvus Met保胰健加

Galvus Met

vildagliptin + metformin

Manufacturer:

Novartis

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Per 50 mg/500 mg Vildagliptin 50 mg, metformin HCl 500 mg. Per 50 mg/850 mg Vildagliptin 50 mg, metformin HCl 850 mg. Per 50 mg/1,000 mg Vildagliptin 50 mg, metformin HCl 1,000 mg
Indications/Uses
Adjunct to diet & exercise in patients w/ type 2 DM whose blood glucose is not adequately controlled on metformin HCl or vildagliptin alone or who are already being treated w/ a free combination of metformin HCl & vildagliptin. In combination w/ sulphonylurea ie, triple combination therapy, as an adjunct to diet & exercise in patients inadequately controlled w/ metformin & sulphonylurea alone. In combination w/ insulin to improve glycemic control in patients whose blood glucose cannot be adequately controlled by diet, exercise & treatment w/ a stable dose of insulin & metformin.
Click to view Galvus Met detailed prescribing information
Dosage/Direction for Use
Inadequately controlled on vildagliptin monotherapy Initially 50 mg/500 mg or 50 mg/850 mg bd. Inadequately controlled on metformin monotherapy Initially 50 mg/500 mg, 50 mg/850 mg or 50 mg/1,000 mg bd. Switching from free combination of metformin & vildagliptin Based on the current dose of metformin or vildagliptin, initiate at 50 mg/500 mg, 50 mg/850 mg or 50 mg/1,000 mg. In combination w/ insulin or sulphonylurea Based on current dose of metformin, 50 mg/500 mg, 50 mg/850 mg or 50 mg/1,000 mg bd.
Click to view Galvus Met detailed prescribing information
Overdosage
View Galvus Met overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food: Take w/ or immediately after meals to reduce GI discomfort.
Contraindications
Hypersensitivity; acute or chronic metabolic acidosis, including lactic acidosis or diabetic ketoacidosis w/ or w/o coma; severe renal impairment (CrCl <30 mL/min); acute conditions which may alter renal function eg, dehydration, severe infection, shock, intravascular administration of iodinated contrast agents; acute or chronic disease which may cause tissue hypoxia eg, heart & resp failure, recent MI & shock; hepatic impairment; acute alcohol intoxication, alcoholism. Lactation.
Click to view Galvus Met detailed prescribing information
Special Precautions
Should not be used in type 1 diabetes or diabetic ketoacidosis. Hypoglycemia. Pregnancy & lactation. Childn. Elderly. Vildagliptin: Hepatic impairment. Perform liver function test prior to & during treatment at 3-mth intervals during the 1st yr & periodically thereafter. Discontinue use if AST/ALT ≥3 x ULN persists, or if jaundice & pancreatitis develop. Cardiac failure (NYHA class III-IV). Monitor for skin disorders eg, blistering & ulceration. Metformin: Discontinue if lactic acidosis is suspected. Renal impairment. Assess GFR before treatment initiation & regularly thereafter. Discontinue prior to or at the time of IV administration of iodinated contrast media & not restarted until at least 48 hr after. Discontinue at the time of surgery under general, spinal & epidural anesth; restart until at least 48 hr after. Avoid alcohol intake. Decreased serum vit B12 levels.
Click to view Galvus Met detailed prescribing information
Adverse Reactions
Nausea; dizziness, tremor. Combination w/ insulin: Decreased blood glucose; headache, chills; nausea, GERD. Combination w/ a sulphonylurea: Hypoglycaemia; dizziness, tremor; hyperhidrosis; asthenia.
Click to view Galvus Met detailed prescribing information
Drug Interactions
Metformin: Increased blood glucose levels w/ glucocorticoids, β2-agonists, diuretics, phenothiazines, thyroid hormones, oestrogens, OCs, hormone replacement therapy, phenytoin, nicotinic acid, Ca channel blockers, INH & tetracosactide. Increased plasma levels w/ furosemide & nifedipine. Increased Cmax & AUC w/ cimetidine. Decreased blood glucose w/ β-blockers & ACE inhibitors. Increased hypoglycaemic effect w/ MAOIs & oral antidiabetics. Potentiated hypoglycaemic effect w/ alcohol. Increased or reduced hypoglycaemic effect w/ H2-antagonists, clonidine & reserpine, quinolones. Increased risk of lactic acidosis w/ diuretics, iodinated contrast media, alcohol, NSAIDs, ACE inhibitors, angiotensin II receptor antagonists. Lowered plasma levels of furosemide. Reduced effect of phenprocoumon. Less perceptible warning signs of hypoglycaemia w/ sympatholytics.
Click to view Galvus Met detailed prescribing information
Storage
View Galvus Met storage conditions for details to ensure optimal shelf-life.
Description
View Galvus Met description for details of the chemical structure and excipients (inactive components).
Action
View Galvus Met mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BD08 - metformin and vildagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Presentation/Packing
Form
Galvus Met 50 mg/1,000 mg film-coated tab
Packing/Price
60's
Form
Galvus Met 50 mg/500 mg film-coated tab
Packing/Price
60's
Form
Galvus Met 50 mg/850 mg film-coated tab
Packing/Price
60's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in